{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:14:20Z","timestamp":1788394460662,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb in collaboration with Exelixis, Ipsen Pharma, and Takeda Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nivolumab plus cabozantinib demonstrated significantly better clinical and patient-reported outcomes (PROs) compared with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) in CheckMate 9ER. This post-hoc analysis identified key factors contributing to improvements in health-related quality of life (HRQOL) in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Mediation analyses were conducted using first-year CheckMate 9ER data to delineate treatment effects as reflected by HRQOL improvements measured with the EuroQoL 5-Dimension 3-Level questionnaire (EQ-5D-3L) and 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) Functional Well-Being Subscale (FKSI-FWB). The incremental benefits of nivolumab plus cabozantinib over sunitinib were partitioned into mediated effects through symptom and emotional well-being improvements (FKSI-19 scales).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nivolumab plus cabozantinib (n\u2009=\u2009323) resulted in significantly greater improvement in EQ-5D utility versus sunitinib (n\u2009=\u2009328; difference = 0.08 [95% confidence interval [CI], 0.05-0.12]) and numerically greater FKSI-FWB improvement (difference = 0.22 [95% CI, \u20130.19 to 0.63]), both primarily driven by greater reductions in fatigue, pain, shortness of breath, and cough, and improvements in emotional well-being (all P\u2009&amp;lt;\u20090.05). Reduced fatigue was the largest contributor to gains in both scales (24.0% and 21.1% of total mediated effect, respectively); improvement in emotional well-being accounted for 5.0% and 17.2% of the total mediated effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings highlight underlying pathways contributing to HRQOL improvement in patients with aRCC receiving nivolumab plus cabozantinib. These data suggest that treatment with nivolumab plus cabozantinib is associated with an improvement in symptoms that can be quantified using PRO measures, supporting the utility of incorporating patient-centric outcomes into treatment decision making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov<\/jats:title>\n                    <jats:p>NCT03141177<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag329","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:12:27Z","timestamp":1786705947000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0037-0303","authenticated-orcid":false,"given":"Cristiane","family":"Bergerot","sequence":"first","affiliation":[{"name":"Oncocl\u00ednicas&Co\u2014Medica Scientia Innovation Research (MEDSIR) , Sao Paulo 01309-001,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-8224","authenticated-orcid":false,"given":"Shengsheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Exelixis, Inc. , Alameda, CA 94502,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-6658","authenticated-orcid":false,"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA 02199,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7484-1011","authenticated-orcid":false,"given":"Bruno","family":"Martins","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA 02199,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtian","family":"Du","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA 02199,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Perez Torrealba","sequence":"additional","affiliation":[{"name":"Exelixis, Inc. , Alameda, CA 94502,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6454-2629","authenticated-orcid":false,"given":"Tasha","family":"Hall","sequence":"additional","affiliation":[{"name":"Exelixis, Inc. , Alameda, CA 94502,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navendu","family":"Samant","sequence":"additional","affiliation":[{"name":"Exelixis, Inc. , Alameda, CA 94502,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-2327","authenticated-orcid":false,"given":"Robert J","family":"Motzer","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-4541","authenticated-orcid":false,"given":"David","family":"Cella","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University , Chicago, IL 60611,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026090219265164100_oyag329-B1","doi-asserted-by":"publisher","first-page":"17588359221108685","DOI":"10.1177\/17588359221108685","article-title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","volume":"14","author":"Lalani","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026090219265164100_oyag329-B2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"2026090219265164100_oyag329-B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14164059","article-title":"Epidemiology and prevention of renal cell carcinoma","volume":"14","author":"Makino","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026090219265164100_oyag329-B4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-020-00195-3","article-title":"Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study","volume":"8","author":"Du","year":"2020","journal-title":"Biomark Res"},{"key":"2026090219265164100_oyag329-B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ucl.2020.04.002","article-title":"Epidemiology, risk assessment, and biomarkers for patients with advanced renal cell carcinoma","volume":"47","author":"Attalla","year":"2020","journal-title":"Urol Clin North Am"},{"key":"2026090219265164100_oyag329-B6","doi-asserted-by":"publisher","first-page":"300060520924265","DOI":"10.1177\/0300060520924265","article-title":"Research progress on advanced renal cell carcinoma","volume":"48","author":"Song","year":"2020","journal-title":"J Int Med Res"},{"key":"2026090219265164100_oyag329-B7","volume-title":"Renal Cell Cancer","author":"Garfield","year":"2024"},{"key":"2026090219265164100_oyag329-B8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2217\/fon-2020-1266","article-title":"Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer","volume":"17","author":"Hall","year":"2021","journal-title":"Future Oncol"},{"key":"2026090219265164100_oyag329-B9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"2026090219265164100_oyag329-B10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(22)00212-1","article-title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026090219265164100_oyag329-B11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/oncolo\/oyae003","article-title":"The relationship between health-related quality of life and overall survival in patients with advanced renal cell carcinoma in CheckMate 214","volume":"29","author":"Cella","year":"2024","journal-title":"Oncologist"},{"key":"2026090219265164100_oyag329-B12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090219265164100_oyag329-B13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026090219265164100_oyag329-B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.2021.39.6_suppl.285","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: the CheckMate 9ER trial","volume":"39","author":"Cella","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090219265164100_oyag329-B15","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1200\/JCO.2023.41.16_suppl.4527","article-title":"Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO\u2009+\u2009CABO) vs sunitinib (SUN) in the CheckMate 9ER trial","volume":"41","author":"Cella","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090219265164100_oyag329-B16","doi-asserted-by":"publisher","first-page":"e2017035","DOI":"10.4178\/epih.e2017035","article-title":"Applied mediation analyses: a review and tutorial","volume":"39","author":"Lange","year":"2017","journal-title":"Epidemiol Health."},{"key":"2026090219265164100_oyag329-B17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.21037\/atm.2016.11.11","article-title":"Causal mediation analysis in the context of clinical research","volume":"4","author":"Zhang","year":"2016","journal-title":"Ann Transl Med"},{"key":"2026090219265164100_oyag329-B18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jval.2013.04.015","article-title":"Development and initial validation of the NCCN\/FACT symptom index for advanced kidney cancer","volume":"16","author":"Rothrock","year":"2013","journal-title":"Value Health"},{"key":"2026090219265164100_oyag329-B19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"2026090219265164100_oyag329-B20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"2026090219265164100_oyag329-B21","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1200\/JCO.2020.38.15_suppl.5083","article-title":"Patient preferences and expectations of systemic therapy in renal cell carcinoma","volume":"38","author":"Battle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090219265164100_oyag329-B22","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2023.41.16_suppl.4560","article-title":"Patient priorities and expectations of systemic therapy in metastatic renal cell carcinoma","volume":"41","author":"Battle","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090219265164100_oyag329-B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1477-7525-5-34","article-title":"Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index","volume":"5","author":"Harding","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"2026090219265164100_oyag329-B24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1634\/theoncologist.2010-0078","article-title":"Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies","volume":"15","author":"Larkin","year":"2010","journal-title":"Oncologist"},{"key":"2026090219265164100_oyag329-B25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.urolonc.2013.09.009","article-title":"A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study","volume":"32","author":"Goebell","year":"2014","journal-title":"Urol Oncol Sem Orig Investigat"},{"key":"2026090219265164100_oyag329-B26","doi-asserted-by":"publisher","first-page":"S309","DOI":"10.1016\/j.jval.2024.03.1955","article-title":"PCR76 exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts","volume":"27","author":"Petit","year":"2024","journal-title":"Value Health"},{"key":"2026090219265164100_oyag329-B27","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/oncolo\/oyad028","article-title":"Patients\u2019 perceptions regarding the relevance of items contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19","volume":"28","author":"Bergerot","year":"2023","journal-title":"Oncologist"},{"key":"2026090219265164100_oyag329-B28","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1038\/s41591-023-02631-x","article-title":"Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma","volume":"29","author":"Fraterman","year":"2023","journal-title":"Nat Med"},{"key":"2026090219265164100_oyag329-B29","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1200\/JCO.2023.41.16_suppl.4540","article-title":"Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D","volume":"41","author":"Bergerot","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090219265164100_oyag329-B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/oncolo\/oyac142","article-title":"Health-related quality of life outcomes with two different starting doses of lenvatinib in combination with everolimus for previously treated renal cell carcinoma","volume":"28","author":"Bergerot","year":"2023","journal-title":"Oncologist"},{"key":"2026090219265164100_oyag329-B31","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.3390\/jcm11216383","article-title":"Psychological distress in patients treated for renal cell carcinoma: a systematic literature review","volume":"11","author":"Vartolomei","year":"2022","journal-title":"J Clin Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag329\/70657438\/oyag329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag329\/70657438\/oyag329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag329\/70657438\/oyag329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:27:00Z","timestamp":1788391620000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag329\/8762014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag329","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag329"}}